Combination therapy for advanced stomach cancer after CLDN18.2 treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that is HER2-negative.
- You have already tried a CLDN18.2-targeted treatment and it stopped working, and it has been at least 2 weeks since your last dose.
- You have at least one measurable tumor on a CT or MRI scan.
- You are between 18 and 75 years old.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your major organs (like bone marrow, liver, kidneys, and heart) are working well based on blood tests and other assessments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
This study tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or GEJ cancer that continued to grow after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.